Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression

The second principal component (PC2) identified 17 analytes that accounted for 17.1% variability in distinguishing primary sclerosing cholangitis (PSC) from healthy controls.

• Significant differences were observed in PC2 between early PSC and controls (p = 0.0001), late PSC and controls (p < 0.0001), and between early and late PSC (p < 0.0001).
• PC2 analytes effectively differentiated early primary biliary cholangitis (PBC) from controls (p < 0.0332), late PBC from controls (p < 0.0001), and early versus late PBC (p < 0.0001).
• PC2 did not differentiate inflammatory bowel disease (IBD) from controls (p = 0.119).
• Logistic regression using PC2 showed strong discrimination for early- and late-stage PSC (AUC = 0.86) and for control versus early-stage PSC (AUC = 0.83).
• The study presents a plasma SASP biomarker signature that may track disease stage in cholestatic liver disease.

AI simplified